Follow us on:

Linkedin Facebook

Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

EDX Medical Group plc

EDX Medical reports 2025 results and advances in cancer diagnostics

EDX Medical Group has published its Annual Report for the year ending 31 March 2025, highlighting the development of a new AI-driven prostate cancer test, a £3 million fundraising, expanded European partnerships, and a service agreement with Royal Marsden NHS Foundation Trust...
Aptamer Group

Aptamer advances enzyme modulation projects and expands pharma collaboration

Aptamer Group announced progress on its Optimer® enzyme modulation projects, including a 10-year non-exclusive licensing deal forecast to cover around 15% of annual overheads and further agreements under discussion with global enzyme distributors...
Convatec Group

Convatec Group Plc launches $300m share buyback programme

Convatec has announced a non-discretionary share buyback of up to $300 million to return surplus capital to shareholders. The programme, managed by UBS AG London Branch, will run until 31 December 2025 and aims to reduce the company’s share capital, with purchased shares either cancelled or held in treasury for employee plans...
Hutchmed

HUTCHMED completes enrollment for phase III SANOVO lung cancer study

HUTCHMED has completed patient enrollment for its Phase III SANOVO trial evaluating ORPATHYS® (savolitinib) with TAGRISSO® (osimertinib) as a first-line treatment for certain EGFR-mutated, MET-overexpressed non-small cell lung cancer patients...
Cizzle Bio

Cizzle Biotechnology to launch CIZ1B cancer test across USA

Cizzle Biotechnology has announced that its North American partner, Cizzle Bio Inc, has signed an agreement with a multi-site accredited laboratory group to roll out the CIZ1B biomarker test for early lung cancer detection across the USA...
Aptamer Group

Aptamer secures contract Eetension with top 5 pharma partner

Aptamer has extended its collaboration with a top 5 global pharmaceutical company to advance Optimer® binders into a fully functional ELISA assay. The agreement builds on the successful completion of the initial binder development phase, with Aptamer retaining IP ownership to support future commercialisation opportunities...
EDX Medical Group plc

Sir Chris Evans on EDX Medical’s partnership to develop rapid pneumonia test (AQSE:EDX)

EDX Medical has teamed up with Cambridge University Hospital's NHS Foundation Trust, the UK Health Security Agency, and other Cambridge institutions to create a rapid digital diagnostic for hospital-acquired pneumonia. The collaboration aims to deliver a reliable test that could save lives, reduce NHS costs, and improve patient outcomes, with development expected to complete later this year...
EDX Medical Group plc

EDX Medical Group: Pioneering the Future of Digital Diagnostics – Oberon Capital

EDX Medical is redefining diagnostics with cutting-edge cancer ‘Super Tests’, rapid sepsis detection & AI-powered pneumonia testing...

EDX Medical Group targets NHS pneumonia cases with breakthrough rapid test partnership (Video)

EDX Medical Group Plc has joined forces with leading NHS and government health bodies to deliver a rapid hospital-acquired pneumonia test. Sir Chris Evans explains why this partnership could change patient outcomes, cut costs, and accelerate the UK’s precision medicine agenda...

Oxford Nanopore CEO Gordon Sanghera to step down

Oxford Nanopore has announced that CEO and co-founder Gordon Sanghera will step down by the end of 2026 after more than 20 years leading the company. The Board has begun a formal search for his successor as part of its succession planning, aiming to guide the business through its next phase of growth and commercialisation...
GSK

GSK’s Gepotidacin receives US FDA Priority Review for gonorrhoea treatment

GSK has announced that the US FDA has accepted for priority review a supplemental New Drug Application for gepotidacin as an oral treatment for uncomplicated urogenital gonorrhoea in patients aged 12 and over...
Nuformix

Nuformix applies for US Orphan Drug Designation for NXP002 in IPF

Nuformix has submitted an application to the US FDA for Orphan Drug Designation for tranilast, the active ingredient in its NXP002 inhaled therapy for idiopathic pulmonary fibrosis...
EDX Medical Group plc

EDX Medical Group to complete the development of new pneumonia test

EDX Medical will partner with the Intensive Care Unit at Cambridge University Hospitals NHS Foundation Trust to support the further advancement of a highly precise test that identifies the DNA or RNA of the microbes that cause lung infection in critically ill patients...
GSK plc

GSK to receive $370m settlement and royalties from mRNA patent agreement

GSK will receive a $370 million upfront payment, plus 1% royalties on US sales of certain mRNA vaccines by BioNTech and Pfizer, following a settlement linked to CureVac’s recent agreement with BioNTech...
Aptamer Group

Aptamer Group to host technical development update webinar

Aptamer will hold a webinar on 14 August 2025 at 6:00 pm BST, led by Chief Scientific Officer Dr David Bunka, to present the latest data and progress across its technical development programmes...
Hikma Pharmaceuticals plc

Hikma Pharmaceuticals reports 6% revenue growth and confirms FY outlook

Hikma Pharmaceuticals posted a 6% rise in H1 2025 revenue to $1.66 billion, supported by strong Injectables and Branded sales. Core operating profit declined 7% due to product mix and prior-year comparators, but the company expects a stronger H2...
Smith & Nephew plc

Smith & Nephew Plc delivers strong H1 with profit up 31%

Smith+Nephew reported 5.0% underlying revenue growth and a 30.6% rise in operating profit for H1 2025. EPS rose 36.6% to 33.5¢ and free cash flow surged to $244m. The company also announced a $500m share buyback for H2, supported by strong cash generation and margin expansion...
Aptamer Group

Aptamer Group reports 41% revenue growth and new licensing deals

Aptamer Group posted unaudited revenue of £1.20 million for the year ended 30 June 2025, up 41% from the previous year. The company secured two new royalty agreements and advanced multiple licensing discussions, supported by a strengthened cash position following a £1.83 million fundraise...
GSK plc

GSK raises 2025 guidance after strong Q2 performance

GSK reported Q2 2025 turnover of £8.0bn, up 6% CER, with strong growth in Specialty Medicines (+15%) and Vaccines (+9%). Core EPS rose 15% to 46.5p...
One Health Group

One Health Group a “buy” in This is Money Midas Share Tips

Analysts at Midas Share Tips described the company as well-managed and well-positioned to benefit from ongoing NHS reliance on external capacity...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest Interviews

BrokerTalk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

EDX Medical Group plc

EDX Medical reports 2025 results and advances in cancer diagnostics

EDX Medical Group has published its Annual Report for the year ending 31 March 2025, highlighting the development of a new AI-driven prostate cancer test, a £3 million fundraising, expanded European partnerships, and a service agreement with Royal Marsden NHS Foundation Trust...
Aptamer Group

Aptamer advances enzyme modulation projects and expands pharma collaboration

Aptamer Group announced progress on its Optimer® enzyme modulation projects, including a 10-year non-exclusive licensing deal forecast to cover around 15% of annual overheads and further agreements under discussion with global enzyme distributors...
Convatec Group

Convatec Group Plc launches $300m share buyback programme

Convatec has announced a non-discretionary share buyback of up to $300 million to return surplus capital to shareholders. The programme, managed by UBS AG London Branch, will run until 31 December 2025 and aims to reduce the company’s share capital, with purchased shares either cancelled or held in treasury for employee plans...
Hutchmed

HUTCHMED completes enrollment for phase III SANOVO lung cancer study

HUTCHMED has completed patient enrollment for its Phase III SANOVO trial evaluating ORPATHYS® (savolitinib) with TAGRISSO® (osimertinib) as a first-line treatment for certain EGFR-mutated, MET-overexpressed non-small cell lung cancer patients...
Cizzle Bio

Cizzle Biotechnology to launch CIZ1B cancer test across USA

Cizzle Biotechnology has announced that its North American partner, Cizzle Bio Inc, has signed an agreement with a multi-site accredited laboratory group to roll out the CIZ1B biomarker test for early lung cancer detection across the USA...
Aptamer Group

Aptamer secures contract Eetension with top 5 pharma partner

Aptamer has extended its collaboration with a top 5 global pharmaceutical company to advance Optimer® binders into a fully functional ELISA assay. The agreement builds on the successful completion of the initial binder development phase, with Aptamer retaining IP ownership to support future commercialisation opportunities...
EDX Medical Group plc

Sir Chris Evans on EDX Medical’s partnership to develop rapid pneumonia test (AQSE:EDX)

EDX Medical has teamed up with Cambridge University Hospital's NHS Foundation Trust, the UK Health Security Agency, and other Cambridge institutions to create a rapid digital diagnostic for hospital-acquired pneumonia. The collaboration aims to deliver a reliable test that could save lives, reduce NHS costs, and improve patient outcomes, with development expected to complete later this year...
EDX Medical Group plc

EDX Medical Group: Pioneering the Future of Digital Diagnostics – Oberon Capital

EDX Medical is redefining diagnostics with cutting-edge cancer ‘Super Tests’, rapid sepsis detection & AI-powered pneumonia testing...

EDX Medical Group targets NHS pneumonia cases with breakthrough rapid test partnership (Video)

EDX Medical Group Plc has joined forces with leading NHS and government health bodies to deliver a rapid hospital-acquired pneumonia test. Sir Chris Evans explains why this partnership could change patient outcomes, cut costs, and accelerate the UK’s precision medicine agenda...

Oxford Nanopore CEO Gordon Sanghera to step down

Oxford Nanopore has announced that CEO and co-founder Gordon Sanghera will step down by the end of 2026 after more than 20 years leading the company. The Board has begun a formal search for his successor as part of its succession planning, aiming to guide the business through its next phase of growth and commercialisation...
GSK

GSK’s Gepotidacin receives US FDA Priority Review for gonorrhoea treatment

GSK has announced that the US FDA has accepted for priority review a supplemental New Drug Application for gepotidacin as an oral treatment for uncomplicated urogenital gonorrhoea in patients aged 12 and over...
Nuformix

Nuformix applies for US Orphan Drug Designation for NXP002 in IPF

Nuformix has submitted an application to the US FDA for Orphan Drug Designation for tranilast, the active ingredient in its NXP002 inhaled therapy for idiopathic pulmonary fibrosis...
EDX Medical Group plc

EDX Medical Group to complete the development of new pneumonia test

EDX Medical will partner with the Intensive Care Unit at Cambridge University Hospitals NHS Foundation Trust to support the further advancement of a highly precise test that identifies the DNA or RNA of the microbes that cause lung infection in critically ill patients...
GSK plc

GSK to receive $370m settlement and royalties from mRNA patent agreement

GSK will receive a $370 million upfront payment, plus 1% royalties on US sales of certain mRNA vaccines by BioNTech and Pfizer, following a settlement linked to CureVac’s recent agreement with BioNTech...
Aptamer Group

Aptamer Group to host technical development update webinar

Aptamer will hold a webinar on 14 August 2025 at 6:00 pm BST, led by Chief Scientific Officer Dr David Bunka, to present the latest data and progress across its technical development programmes...
Hikma Pharmaceuticals plc

Hikma Pharmaceuticals reports 6% revenue growth and confirms FY outlook

Hikma Pharmaceuticals posted a 6% rise in H1 2025 revenue to $1.66 billion, supported by strong Injectables and Branded sales. Core operating profit declined 7% due to product mix and prior-year comparators, but the company expects a stronger H2...
Smith & Nephew plc

Smith & Nephew Plc delivers strong H1 with profit up 31%

Smith+Nephew reported 5.0% underlying revenue growth and a 30.6% rise in operating profit for H1 2025. EPS rose 36.6% to 33.5¢ and free cash flow surged to $244m. The company also announced a $500m share buyback for H2, supported by strong cash generation and margin expansion...
Aptamer Group

Aptamer Group reports 41% revenue growth and new licensing deals

Aptamer Group posted unaudited revenue of £1.20 million for the year ended 30 June 2025, up 41% from the previous year. The company secured two new royalty agreements and advanced multiple licensing discussions, supported by a strengthened cash position following a £1.83 million fundraise...
GSK plc

GSK raises 2025 guidance after strong Q2 performance

GSK reported Q2 2025 turnover of £8.0bn, up 6% CER, with strong growth in Specialty Medicines (+15%) and Vaccines (+9%). Core EPS rose 15% to 46.5p...
One Health Group

One Health Group a “buy” in This is Money Midas Share Tips

Analysts at Midas Share Tips described the company as well-managed and well-positioned to benefit from ongoing NHS reliance on external capacity...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest interviews

Broker Talk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

Latest Interviews

FTSE 100 News

FTSE 250 News

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

BrokerTalk

FTSE 100

Funds

View all Funds, Market Insights and news >> 

Green News

View all Sustainable sectors, Plcs and news >>  

UK Broker Ratings

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple